Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Stock analysts at HC Wainwright issued their FY2029 earnings estimates for Merus Labs International in a research report issued to clients and investors on Thursday, March 27th. HC Wainwright analyst A. He forecasts that the specialty pharmaceutical company will post earnings of ($0.13) per share for the year.
Merus Labs International Stock Performance
The firm has a fifty day moving average price of C$1.65. Merus Labs International has a twelve month low of C$0.95 and a twelve month high of C$1.76.
Merus Labs International Company Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Read More
- Five stocks we like better than Merus Labs International
- What is Short Interest? How to Use It
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- What Are Some of the Best Large-Cap Stocks to Buy?
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
